This Pre-Solicitation opportunity from Department Of Health And Human Services was posted on May 14, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.
BIO RAD LABORATORIES INC. – LIQUICHEK TUMOR REGEANTS
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
Active Opportunities Like This One
AI Contract Overview
The National Institutes of Health (NIH) Clinical Center plans to award a sole source firm-fixed-price contract to Bio-Rad Laboratories for the supply of Liquichek Tumor Reagents. These reagents are critical testing controls used in the Department of Laboratory Medicine’s Immunoassay laboratory to monitor cardiac, cancer, and infectious disease markers. The contract supports ongoing clinical protocols that require consistent and reliable testing over time, as many research efforts span several years, necessitating stable laboratory values achieved through the same testing methodologies and instrumentation. This acquisition is justified by the fact that Bio-Rad Laboratories is the sole manufacturer of Liquichek Tumor Reagents, and no substitutions are allowed without extensive revalidation and regulatory approval, which could jeopardize patient care. The procurement is conducted under FAR 13.106-1(b)(1), allowing solicitation from a single source. While this notice is for informational purposes and not a solicitation, interested parties may submit capability statements demonstrating their qualifications, including company details, technical capabilities, OEM authorization, and relevant past performance by May 24, 2026. The ultimate decision not to compete rests solely with the Government.
General Info
Agency
NAICS
Place of Performance
Bethesda, MD, 20892, USASet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Submission Closed
Organization & Contact Information
Full Description
Place of Performance:
National Institutes of Health
Clinical Center
Bethesda, MD 20892
POTS: 26-005107
Description
This notice is issued for informational purposes only and does not constitute a request for quotations. A solicitation will not be issued, and quotations will not be requested.
The National Institutes of Health (NIH), Clinical Center, intends to award a sole source firm-fixed-price contract to Bio-Rad Laboratories for the procurement of Liquichek Tumor Regeants.
The requirement consists of testing controls for cardiac, cancer and infectious disease markers for Liquichek Tumor Regeants, which provide consistent, high-quality results for clinical center patients within the Department of Laboratory Medicine (DLM) Immunoassay laboratory.
Background
The Department of Laboratory Medicine (DLM) Immunoassay laboratory currently provides services for 35 protocols across several Institutes, and they all require highly accurate and rapid results. In addition, some research protocols extend over several years, it is very important for laboratory values to remain consistent over time through the same testing methodologies and similar instrumentation.
Rationale:
Bio-Rad Laboratories is the sole manufacturer of Liquichek Tumor Regeants. Substitution is not permissible without revalidation and regulatory approval, which could delay treatment and pose risks to patient care
Authority
This acquisition is being conducted in accordance with:
FAR 13.106-1(b)(1) – Soliciting from a Single Source
Under this authority, the Contracting Officer may solicit from a single source when it is determined that only one source is reasonably available to meet the Government’s requirements.
Acquisitions conducted under FAR Part 13 – Simplified Acquisition Procedures are exempt from the competition requirements of FAR Part 6.
Responses
This is not a request for quotations. However, interested parties may submit a capability statement demonstrating their ability to meet the Government’s requirement.
Responses must include:
- Company name and address
- Technical capability
- Proof of OEM authorization
- Relevant past performance
The Government will evaluate capability statements received in response to this notice. The determination not to compete this requirement is solely within the discretion of the Government.
Submission Instructions
Responses referencing POTS: 26-005107 must be submitted electronically no later than May 24, 2026, at 8:00 AM EST to:
Gregory Noland
Hospital and Laboratory Support Division
Office of Acquisitions and Logistics Management
National Institutes of Health
Email: gregory.noland@nih.gov